Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia

Varun Bafna, Sandip Shah, Arijit Nag, Prof. Uttam Kumar Nath, Chandran Nair, Ramesh Uppada, Devan Bursey, Andrea Groen, Victoria Allgood, Alan List, Stephen Anthony, David Bearss

Blood (2025) 146 (Supplement 1): 5622.

https://doi.org/10.1182/blood-2025-5622

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Delta opiod receptor signaling modulates myeloid suppression in Myelodysplastic Syndromes

Tiffany Razabdouski, KRIT Ritthipichai, Pingyan Cheng, Ruihua Chen, Bertrand Le Bourdonnec, Thierry Guillaudeux, Ken Wright, Alan List, James Bianco, Erika Eksioglu

Blood (2025) 146 (Supplement 1): 3841.

https://doi.org/10.1182/blood-2025-3841

Published: 2025

Journal Articles

Ofirnoflast, a novel inflammasome inhibitor, rewires transcriptional programs and shows clinical and preclinical efficacy in myeloid neoplasms

Blood (2025) 146 (Supplement 1): 323.

https://doi.org/10.1182/blood-2025-323

Published: 2025

Journal Articles

Monoclonal antibodies against pathogenic S100A8/9 alarmins can restore hematopoiesis and result in immunomodulation in myelodysplasia and leukemia models

Rahul Sanawar, Ariel Fromowitz, Srinivas Aluri, Sarah Aminov, Srabani Sahu, Leah Kravets, Shanisha Gordon-Mitchell, Mani Mohindru, Aditi Shastri, Alan List, Eric Padron, Rongbao Zhao, Amit Verma

Blood (2025) 146 (Supplement 1): 4959.

https://doi.org/10.1182/blood-2025-4959

Published: 2025

Journal Articles

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

Usama Gergis, Aaron Martin, Alex Vogel, Jeff Smith, Andreas Klein, Ran Reshef, Rajneesh Nath, Adam J. Olszewski, Alan List, Alex F. Herrera, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7175.

https://doi.org/10.1182/blood-2024-210499

Published: 2024

Journal Articles

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

David A. Sallman, Alan List

Blood (2019) 133 (10): 1039–1048.

https://doi.org/10.1182/blood-2018-10-844654

Published: 2019

Journal Articles

Whole Exome Sequencing (“mutatome”) Of Deletion 5q

Naoko Hosono, MD, PhD, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, PhD, Andres Jerez, MD, Chantana Polprasert, MD, Yuichi Shiraishi, PhD, Kenichi Chiba, PhD, Hiroko Tanaka, BA, Satoru Miyano, PhD, Kenichi Yoshida, MD, Masashi Sanada, MD, PhD, Jacqueline Boultwood, PhD, Alan List, MD, Mikkael A. Sekeres, MD, MS, Seishi Ogawa, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2013) 122 (21): 656.

https://doi.org/10.1182/blood.V122.21.656.656

Published: 2013

Journal Articles

Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases

Rami S Komrokji, MD, Austin G Kulasekararaj, MBBS, MD, MRCP, FRCP, Najla H Al Ali, Shahram Y Kordasti, MD, PhD, Emily Bart-smith, Craig Benjamin, Eric Padron, MD, Ling Zhang, MD, Jeffrey E Lancet, MD, Alan List, MD, Ghulam J Mufti, FRCP, FRCPath, M.D., Pearlie K Epling-Burnette, PhD

Blood (2013) 122 (21): 746.

https://doi.org/10.1182/blood.V122.21.746.746

Published: 2013

Journal Articles

Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice

Pearlie K Epling-Burnette, PhD, Ying Han, MD, Adam W Mailloux, PhD, Ling Zhang, MD, Jessica M. McDaniel, PhD, Rajadhyaksha Anjali, PhD, Sheng Wei, MD, Ritchie David, PhD, Paul Neeson, PhD, Rami S. Komrokji, MD, Alan List, MD

Blood (2013) 122 (21): 748.

https://doi.org/10.1182/blood.V122.21.748.748

Published: 2013

Journal Articles

Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium

Rami S Komrokji, MD, Xiao-Feng Wang, phD, Najla H Al Ali, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Gail J. Roboz, MD, Steven D Gore, Sean Hobson, Cassandra Zimmerman, Eric Padron, MD, Jaroslaw P. Maciejewski, MD, PhD, Alan List, MD, Mikkael A. Sekeres, MD, MS

Blood (2013) 122 (21): 1505.

https://doi.org/10.1182/blood.V122.21.1505.1505

Published: 2013

Journal Articles

A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients

Rami S Komrokji, MD, Najla H Al Ali, Eric Padron, MD, Ji-Hyun Lee, PhD, Nancy Hillgruber, RN, Sara Tinsley, ARNP, Jeffrey E Lancet, MD, Alan List, MD

Blood (2013) 122 (21): 1506.

https://doi.org/10.1182/blood.V122.21.1506.1506

Published: 2013

Journal Articles

Lenalidomide Treatment For Lower Risk Non-Deletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Prior To Azanucleosides

Rami S Komrokji, MD, Maria G. Corrales-Yepez, MD, Najla H Al Ali, Eric Padron, MD, Jeffrey E Lancet, MD, Alan List, MD

Blood (2013) 122 (21): 1507.

https://doi.org/10.1182/blood.V122.21.1507.1507

Published: 2013

Journal Articles

Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Maria Gabriela Corrales-Yepez, MD, Teresa Field, MD, PhD, Alan List, MD, Claudio Anasetti, MD, Janelle Perkins, PharmD, Najla H Al Ali, Asmita Mishra, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Mohamed A. Kharfan-Dabaja, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 5222.

https://doi.org/10.1182/blood.V122.21.5222.5222

Published: 2013

Journal Articles

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Ryan Hillgruber, Taiga Nishihori, MD, Asmita Mishra, MD, Joseph Pidala, MD, MS, Ernesto Ayala, MD, Frederick L Locke, MD, Melissa Alsina, MD, Brian C. Betts, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Alan List, MD, Rami S Komrokji, MD, Mohamed A. Kharfan-Dabaja, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2152.

https://doi.org/10.1182/blood.V122.21.2152.2152

Published: 2013

Journal Articles

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

Viet Q. Ho, PharmD, BCOP, Robert Cade, PharmD, Gene A. Wetzstein, PharmD, BCOP, Van D Hoang, PharmD, BCOP, Alan List, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 3951.

https://doi.org/10.1182/blood.V122.21.3951.3951

Published: 2013

Journal Articles

Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study

Prerna Rastogi, MBBS, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Eric Padron, MD, Elizabeth M. Sagatys, MD, Mojdeh Naghashpour, MD, PhD, Jiangchuan Tao, MD, PhD, John M. Bennett, Alan List, MD, Jeffrey E Lancet, MD, Kenneth S. Zuckerman, MD, Ling Zhang, MD

Blood (2013) 122 (21): 4076.

https://doi.org/10.1182/blood.V122.21.4076.4076

Published: 2013

Journal Articles

Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004

Aristoteles Giagounidis, MD, PhD, Alan List, MD, Eva Hellström-Lindberg, MD, PhD, Mikkael A. Sekeres, MD, MS, Ghulam J. Mufti, MD, PhD, Brigitte Schlegelberger, MD, PhD, John Morrill, Chengqing Wu, Barry S. Skikne, MD, Pierre Fenaux, MD, PhD, Gudrun Göhring, MD

Blood (2013) 122 (21): 1538.

https://doi.org/10.1182/blood.V122.21.1538.1538

Published: 2013

Journal Articles

Aberrant Overexpression Of CD14 In Granulocytes Sensitizes Innate Immune Response In mDia1 Heterozygous Myelodysplastic Syndromes

Ganesan Keerthivasan, MBBS, MD, Baobing Zhao, PhD, Chad E Harris, Ling Zhang, MD, Juehua Gao, M.D., Ph.D., James McElherne, Jing Yang, Ashley A Basiorka, Matthew Schipma, Jacqueline Boultwood, Amit Verma, Alan List, MD, David A. Williams, MD, Peng Ji, MD, PhD

Blood (2013) 122 (21): 1557.

https://doi.org/10.1182/blood.V122.21.1557.1557

Published: 2013

Journal Articles

A Sequential Two-Stage Dose Escalation Study Evaluating The Safety and Efficacy Of Eltrombopag In Thrombocytopenic Patients With Myelodysplastic Syndrome (MDS) Resistant To Hypomethylating Agents (HMA)

Rami S Komrokji, MD, Vu H. Duong, M.D., Ling Zhang, MD, Ji-Hyun Lee, PhD, Eric Padron, MD, Jeffrey E Lancet, MD, Alan List, MD

Blood (2013) 122 (21): 2760.

https://doi.org/10.1182/blood.V122.21.2760.2760

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Delta opiod receptor signaling modulates myeloid suppression in Myelodysplastic Syndromes

Ofirnoflast, a novel inflammasome inhibitor, rewires transcriptional programs and shows clinical and preclinical efficacy in myeloid neoplasms

Monoclonal antibodies against pathogenic S100A8/9 alarmins can restore hematopoiesis and result in immunomodulation in myelodysplasia and leukemia models

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Whole Exome Sequencing (“mutatome”) Of Deletion 5q

Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases

Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice

Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium

A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients

Lenalidomide Treatment For Lower Risk Non-Deletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Prior To Azanucleosides

Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study

Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004

Aberrant Overexpression Of CD14 In Granulocytes Sensitizes Innate Immune Response In mDia1 Heterozygous Myelodysplastic Syndromes

A Sequential Two-Stage Dose Escalation Study Evaluating The Safety and Efficacy Of Eltrombopag In Thrombocytopenic Patients With Myelodysplastic Syndrome (MDS) Resistant To Hypomethylating Agents (HMA)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only